{"nctId":"NCT01614886","briefTitle":"Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","startDateStruct":{"date":"2012-07"},"conditions":["Alzheimer's Disease"],"count":216,"armGroups":[{"label":"1 step","type":"EXPERIMENTAL","interventionNames":["Drug: Active Comparator"]},{"label":"3 step","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ENA713"]}],"interventions":[{"name":"Active Comparator","otherNames":[]},{"name":"ENA713","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria\n* A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria\n* An MMSE score of ≥ 10 and ≤ 20 at baseline\n\nExclusion Criteria:\n\n* Any medical or neurological conditions other than AD that could explain the patient's dementia\n* A current diagnosis of probable or possible vascular dementia\n* A score of \\> 5 on the Modified Hachinski Ischemic Scale (MHIS)\n* A current DSM-IV Axis 1 diagnosis that may interfere with the evaluation of the patient's response to study medication.\n* Treated with donepezil or galantamine within last 4 weeks before the efficacy assessment at baseline.\n* an advanced severe progressive or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient's at special risk\n* Other protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Patients With Adverse Events Leading to Study Drug Discontinuation","description":"The primary variable of this study is the percentage of patients having an AE leading to study drug discontinuation during the 24-week double-blind treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"18.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)","description":"The Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) was used to measure change in cognitive function. The ADAS-J cog score ranges from 0-70, with higher total scores indicating more impairment. A negative change score indicates improvement from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"3.94"},{"groupId":"OG001","value":"-0.9","spread":"4.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"5.01"},{"groupId":"OG001","value":"-1.2","spread":"5.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"4.66"},{"groupId":"OG001","value":"-1.8","spread":"5.58"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mini-Mental State Examination (MMSE)","description":"The MMSE was used to measure severity of Alzheimer's disease. The test consists of 2 parts: language (time orientation, registration and attention) and performance (recall, response to written/verbal commands, sriting ability and reproduction of complex polygons); the total score can range from 0 to 30, with a higher score indicating better function. A positive change score indicates improvement from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"2.91"},{"groupId":"OG001","value":"0.5","spread":"3.15"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Improvement in Japanese Clinical Global Impression of Change (J-CGIC). Patients With \"Improvement\": a Total of 1. Markedly Improved, 2. Improved, and 3. Slightly","description":"The J-CGIC is simple 7 grade investigator's impression scale (1. Markedly improved, 2. Improved, 3. Slightly improved, 4. No change, 5. Slightly aggravated, 6. Aggravated, 7. Markedly aggravated) and a patient is defined to have improvement if J-CGIC tool the values 1, 2, or 3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Treatment Retention.","description":"Treatment retention rate at effective dose is defined as the proportion of patients who met all the followings - 1) completed the study, 2) received rivastigmine patch 18 mg/day throughout the last 8 weeks 3) received 18 mg/day for ≥75% of the days during the last 8 weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"69.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":107},"commonTop":["Application site pruritus","Application site erythema","Dermatitis contact","Nasopharyngitis","Nausea"]}}}